Autologous Platelet-rich Plasma in the Treatment of Persistent Epithelial Defects
Autologous Platelet-rich Plasma in the Treatment of Persistent Corneal Epithelial Defects
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Karim Mohamed-Noriega, M.D.
- Phone Number: +52 8183469259
- Email: karim.mohamednrg@uanl.edu.mx
Study Locations
-
-
Nuevo León
-
Monterrey, Nuevo León, Mexico, 64460
- Recruiting
- Departamento de Oftalmologia, Hospital Universitario "Dr. Jose Eleuterio Gonzalez"
-
Contact:
- Karim Mohamed-Noriega, M.D.
- Phone Number: +52 81 83469259
- Email: karim.mohamednrg@uanl.edu.mx
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Patients with persistent epithelial defect and at least one of the following diagnoses:
- Recurrent corneal epithelial defect.
- Neurotrophic corneal ulcer.
- Neurotrophic keratopathy secondary to any disease (i.e. diabetes mellitus, infection with herpes simplex virus or herpes zoster virus, microbial keratitis sequelae, multiple sclerosis, Parkinson's disease, VII cranial nerve palsy, chemical or thermic burn sequelae, trauma, surgery, iatrogenic, chronic dry eye, rheumatic disease).
Exclusion Criteria:
Patients diagnosed with:
- Peripheral ulcerative keratitis, or Mooren's ulcer.
- Active infectious keratitis and/or ulcers.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: PRP plus BCL
Bandage contact lens (BCL) plus 1 autologous platelet-rich plasma (PRP) eye drop every 1 to 3 hours.
|
Bandage contact lens (BCL) plus 1 autologous platelet-rich plasma (PRP) eye drop every 1 to 3 hours.
|
|
Active Comparator: BCL plus PFL
Bandage contact lens (BCL) plus 1 preservative-free lubricant (PFL) eye drop every 1 to 3 hours.
|
Bandage contact lens (BCL) plus 1 preservative-free lubricant (PFL) eye drop every 1 to 3 hours.
|
|
Active Comparator: Eye patch plus ocular lubricant ointment
Eye patch plus ocular lubricant ointment every 24 hours.
|
Eye patch plus ocular lubricant ointment every 24 hours.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Persistent epithelial defect healing time.
Time Frame: From the first day of treatment until the date of complete defect closure, assessed up to 3 months.
|
Persistent epithelial defect healing time measured in days.
|
From the first day of treatment until the date of complete defect closure, assessed up to 3 months.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in corneal sensitivity
Time Frame: Change from baseline corneal sensitivity at the date of defect closure, up to 3 months.
|
Corneal sensitivity will be assessed with corneal esthesiometer Cochet-Bonnet.
|
Change from baseline corneal sensitivity at the date of defect closure, up to 3 months.
|
|
Uncorrected visual acuity
Time Frame: Every week (or sooner, if needed) from date of randomization until the date of complete defect closure, up to 3 months.
|
Uncorrected visual acuity will be assessed using Snellen cards.
Measurements will be converted to LogMar values for statistical analysis.
|
Every week (or sooner, if needed) from date of randomization until the date of complete defect closure, up to 3 months.
|
|
Best corrected visual acuity
Time Frame: Every week (or sooner, if needed) from date of randomization until the date of complete defect closure, up to 3 months.
|
Best corrected visual acuity will be assessed using Snellen cards.
Measurements will be converted to LogMar values for statistical analysis.
|
Every week (or sooner, if needed) from date of randomization until the date of complete defect closure, up to 3 months.
|
|
Ocular pain
Time Frame: Every week (or sooner, if needed) from date of randomization until the date of complete defect closure, up to 3 months.
|
Ocular pain will be assessed using the Wong-Baker Faces Pain Rating Scale.
The scale ranges from 0 (no pain) to 10 (maximum pain), and includes 6 faces (visual representation), numbers, and written descriptions that represent the level of pain.
The first face represents a pain score of 0 and it reads "no hurt"; the second face represents a pain score of 2 and it reads "hurts little bit"; the third face represents a pain score of 4 and it reads "hurts little more"; the fourth face represents a pain score of 6 and it reads "hurts even more"; the fifth face represents a pain score of 8 and it reads "hurts whole lot"; the last face represents a pain score of 10 and it reads "hurst worst".
Lower values represent a better outcome.
|
Every week (or sooner, if needed) from date of randomization until the date of complete defect closure, up to 3 months.
|
|
Ocular surface symptoms
Time Frame: Every week (or sooner, if needed) from date of randomization until the date of complete defect closure, up to 3 months.
|
Ocular surface symptoms as assessed by the Symptom Assessment in Dry Eye (SANDE) questionnaire.
The SANDE questionnaire consists of two questions presented in visual analog scale.
The first question assesses the frequency of dry eye syndrome and the scale ranges from "rarely" to "all the time" on a 100 mm line.
The second question assesses the severity of dry eye syndrome and the scale ranges from "very mild" to "very severe" on a 100 mm line.
Patients are asked to place a mark on the line to represent the extent of their symptoms, then the location of the marks on each line are measured from left to right in mm.
The SANDE score is calculated by multiplying the frequency value times the severity value and obtaining the square root.
Lower scores represent a better outcome.
|
Every week (or sooner, if needed) from date of randomization until the date of complete defect closure, up to 3 months.
|
|
Ocular surface symptoms
Time Frame: At date of randomization and at date of defect closure, up to 3 months.
|
Ocular surface symptoms as assessed by the Ocular Surface Disease Index (OSDI).
The OSDI questionnaire consists of 12 questions that assess dry eye symptoms and their effects on vision related function.
The questionnaire is divided in 3 subscales: ocular symptoms, vision-related function, and environmental triggers.
Patients are asked to rate their responses on a 0 to 4 scale where 0 represents "none of the time", 1 "some of the time", 2 "half of the time", 3 "most of the time", and 4 "all of the time".
The total score is calculated using the following formula: ([sum of scores for all questions answered x 100] / [total number of questions answered x 4]).
Lower scores represent a better outcome.
|
At date of randomization and at date of defect closure, up to 3 months.
|
|
Quality of life questionnaire
Time Frame: At date of randomization and at date of defect closure, up to 3 months.
|
Quality of life as assessed by the National Eye Institute Visual Function Questionnaire (NEI VFQ-25).
The NEI VFQ-25 questionnaire consists of 25 questions that assess the effect of visual impairment on the patient's quality of life.
The 25-item questionnaire gives a score on a scale of 0 to 100, where 0 is the worst score and 100 is the best score.
Higher scores represent a better outcome.
|
At date of randomization and at date of defect closure, up to 3 months.
|
|
Frequency of adverse events, recurrences and/or treatment failure
Time Frame: These will be evaluated from the beginning of the treatment until three months after defect closure.
|
Frequency of adverse events, recurrences and/or treatment failure will be evaluated during the ophthalmic evaluation.
|
These will be evaluated from the beginning of the treatment until three months after defect closure.
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Karim Mohamed-Noriega, M.D., Departamento de Oftalmologia, Hospital Universitario Dr. Jose Eleuterio Gonzalez
Publications and helpful links
General Publications
- Tsubota K, Goto E, Shimmura S, Shimazaki J. Treatment of persistent corneal epithelial defect by autologous serum application. Ophthalmology. 1999 Oct;106(10):1984-9. doi: 10.1016/S0161-6420(99)90412-8.
- Chen J, Chen P, Backman LJ, Zhou Q, Danielson P. Ciliary Neurotrophic Factor Promotes the Migration of Corneal Epithelial Stem/progenitor Cells by Up-regulation of MMPs through the Phosphorylation of Akt. Sci Rep. 2016 May 13;6:25870. doi: 10.1038/srep25870.
- Ljubimov AV, Saghizadeh M. Progress in corneal wound healing. Prog Retin Eye Res. 2015 Nov;49:17-45. doi: 10.1016/j.preteyeres.2015.07.002. Epub 2015 Jul 18.
- Nugent RB, Lee GA. Ophthalmic use of blood-derived products. Surv Ophthalmol. 2015 Sep-Oct;60(5):406-34. doi: 10.1016/j.survophthal.2015.03.003. Epub 2015 Apr 15.
- Alio JL, Rodriguez AE, WrobelDudzinska D. Eye platelet-rich plasma in the treatment of ocular surface disorders. Curr Opin Ophthalmol. 2015 Jul;26(4):325-32. doi: 10.1097/ICU.0000000000000169.
- Alio JL, Abad M, Artola A, Rodriguez-Prats JL, Pastor S, Ruiz-Colecha J. Use of autologous platelet-rich plasma in the treatment of dormant corneal ulcers. Ophthalmology. 2007 Jul;114(7):1286-1293.e1. doi: 10.1016/j.ophtha.2006.10.044. Epub 2007 Feb 26.
- Kim KM, Shin YT, Kim HK. Effect of autologous platelet-rich plasma on persistent corneal epithelial defect after infectious keratitis. Jpn J Ophthalmol. 2012 Nov;56(6):544-50. doi: 10.1007/s10384-012-0175-y. Epub 2012 Sep 13.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- OF18-00003
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.